COMMUNIQUÉS West-GlobeNewswire

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
18/10/2025
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 demonstrated 50% confirmed objective response rate (ORR), [...]
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
18/10/2025
Study data also showed prolonged progression-free survival with 177 Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading [...]

Pages